January 2017 Issue of MMM
Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can ...
This month we will debut a restyled MM&M logo on our website, in a mobile-friendly, redesigned email newsletter, and on the cover of our magazine.
Here you'll find everything you need to know from MM&M's January 2017 issue, including our health-tech preview, a deep dive into data science, and report ...
Read more to learn what Startup Health's Unity Stoakes and UCB's Greg Cohen, and others have to say about the latest trends for 2017.
Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.
The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.
The first step is to seek leadership support, she says.
When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.
Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.
Nobody knows what the future holds for the Affordable Care Act under the Trump administration and an emboldened Republican Congress.
"In Australia, we are the healthcare industry," he says.
Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their ...
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients ...
The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.
Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.
As the effectiveness of in-person detailing wanes, how will cloud-based content solutions adapt?
Peter Pitts calls for Trump to eliminate the Independent Payment Advisory Board and direct the FDA to issue guidance on off-label communications.
We should make off-label research publicly available in a non-promotional format to both healthcare professionals and patients.
There's a reason pharma lags on the programmatic adoption curve: It's a heavily regulated industry, and there are concerns around privacy.
Here are six campaigns that connect with the patient on a personal level.
At Work With
The chief creative officer at Carling Communications talks about how she learned that the best leaders are only as good as the performance of their ...
In short, CEOs can't be afraid to walk away from their most profitable line if another approach may lead to improved long-term outcomes.